REGN vs AMGN
REGN and AMGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | REGNREGENERON PHARMACEUTICALS, INC. | AMGNAmgen Inc. |
|---|---|---|
| Market cap | — | $210.12B |
| P/E (TTM) | 17.0 | 27.1 |
| P/B | — | 22.86 |
| P/S | — | 5.8x |
| Dividend yield | — | 2.44% |
| Revenue | $14.92B(TTM) | $37.22B(TTM) |
| Revenue growth (YoY) | 1.0% | 10.0% |
| Net income | $4.42B(TTM) | $7.80B(TTM) |
| Earnings growth (YoY) | 2.1% | 88.5% |
| EPS, diluted | $40.96(TTM) | $14.37(TTM) |
| EBIT margin | 24.9% | 24.7% |
| ROE | 14.3% | 83.9% |
| ROIC | 9.6% | 15.3% |
| 1y total return | +24.6% | +32.7% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: REGN vs AMGN
| Metric | REGN | AMGN |
|---|---|---|
| End value | $19.3K | $35.6K |
| Total return | +92.8% | +255.9% |
| CAGR | +6.6% | +13.1% |
| Volatility | 32.4% | 24.8% |
| Sharpe | 0.24 | 0.46 |
| Sortino | 0.35 | 0.69 |
| Max drawdown | -59.7% | -24.9% |
Based on 2600 common trading days, 2016-03-28 → 2026-07-29 · risk-free 3.9% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)